Total Payments
$4,443
2024 Payments
$607.41
Companies
42
Transactions
322
Medicare Patients
2,624
Medicare Billing
$318,410
Payment Breakdown by Category
Food & Beverage$4,353 (98.0%)
Gifts$73.31 (1.7%)
Education$16.35 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,353 | 319 | 98.0% |
| Gift | $73.31 | 1 | 1.7% |
| Education | $16.35 | 2 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,098 | 88 | $0 (2024) |
| Novo Nordisk Inc | $623.72 | 47 | $0 (2024) |
| Lilly USA, LLC | $369.88 | 28 | $0 (2024) |
| PFIZER INC. | $285.03 | 25 | $0 (2021) |
| Upsher-Smith Laboratories LLC | $164.83 | 12 | $0 (2020) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $142.38 | 8 | $0 (2021) |
| GlaxoSmithKline, LLC. | $132.42 | 9 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $125.76 | 10 | $0 (2024) |
| Braintree Laboratories, Inc. | $113.41 | 4 | $0 (2021) |
| Allergan, Inc. | $106.80 | 8 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $607.41 | 37 | ABBVIE INC. ($302.92) |
| 2023 | $399.42 | 31 | AbbVie Inc. ($242.89) |
| 2022 | $553.63 | 41 | ABBVIE INC. ($261.55) |
| 2021 | $801.60 | 63 | AbbVie Inc. ($209.69) |
| 2020 | $639.39 | 40 | Novo Nordisk Inc ($153.67) |
| 2019 | $299.87 | 23 | Upsher-Smith Laboratories LLC ($90.80) |
| 2018 | $588.16 | 49 | PFIZER INC. ($161.57) |
| 2017 | $553.35 | 38 | Novo Nordisk Inc ($68.77) |
All Payment Transactions
322 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/20/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $44.00 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/19/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: Obesity | ||||||
| 11/12/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $6.59 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/12/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $4.49 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.42 | General |
| Category: NEUROSCIENCE | ||||||
| 10/23/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: PSYCHIATRY | ||||||
| 10/21/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 10/17/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: Diabetes | ||||||
| 10/15/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $29.68 | General |
| Category: NEUROSCIENCE | ||||||
| 09/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.94 | General |
| Category: NEUROSCIENCE | ||||||
| 09/17/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: Inflammation | ||||||
| 09/16/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $20.68 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 08/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $28.09 | General |
| Category: NEUROSCIENCE | ||||||
| 07/23/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: Diabetes | ||||||
| 06/26/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $31.03 | General |
| Category: NEUROSCIENCE | ||||||
| 06/06/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $16.16 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/06/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $2.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/04/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.49 | General |
| Category: NEUROSCIENCE | ||||||
| 05/29/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $1.99 | General |
| Category: NEUROSCIENCE | ||||||
| 05/14/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $19.59 | General |
| Category: Biological | ||||||
| 05/09/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: Inflammation | ||||||
| 04/17/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $13.55 | General |
| Category: Diabetes | ||||||
| 04/16/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $25.36 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 403 | 801 | $125,116 | $62,449 |
| 2022 | 11 | 510 | 1,137 | $141,701 | $67,744 |
| 2021 | 16 | 744 | 1,592 | $196,189 | $93,438 |
| 2020 | 16 | 967 | 1,944 | $234,924 | $94,779 |
Total Patients
2,624
Total Services
5,474
Medicare Billing
$318,410
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 132 | 433 | $91,796 | $46,663 | 50.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 88 | 146 | $23,068 | $11,028 | 47.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 56 | 56 | $2,016 | $1,558 | 77.3% |
| 90688 | Influenza vaccine, quadrivalent, 0.5 ml dosage | Office | 2023 | 57 | 57 | $1,482 | $1,165 | 78.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 20 | 24 | $2,568 | $1,079 | 42.0% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 20 | 24 | $1,488 | $565.44 | 38.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 15 | 44 | $2,596 | $352.84 | 13.6% |
| 81003 | Automated urinalysis test | Office | 2023 | 15 | 17 | $102.00 | $37.40 | 36.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 143 | 433 | $91,796 | $47,901 | 52.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 110 | 188 | $29,704 | $13,109 | 44.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 59 | 60 | $2,160 | $1,580 | 73.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 27 | 35 | $3,745 | $1,532 | 40.9% |
| 90688 | Influenza vaccine, quadrivalent, 0.5 ml dosage | Office | 2022 | 60 | 61 | $1,586 | $1,203 | 75.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 12 | 15 | $3,510 | $1,058 | 30.1% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 33 | 37 | $2,294 | $634.55 | 27.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 17 | 60 | $3,540 | $506.90 | 14.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 21 | 22 | $990.00 | $153.53 | 15.5% |
| 81003 | Automated urinalysis test | Office | 2022 | 16 | 22 | $132.00 | $48.78 | 37.0% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 12 | 204 | $2,244 | $16.49 | 0.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 138 | 389 | $82,468 | $44,250 | 53.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 183 | 478 | $75,524 | $36,350 | 48.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 69 | 106 | $11,342 | $5,443 | 48.0% |
| 71046 | X-ray of chest, 2 views | Office | 2021 | 49 | 62 | $3,844 | $1,271 | 33.1% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 12 | 14 | $3,276 | $1,135 | 34.6% |
| 20610 | Aspiration and/or injection of large joint or joint capsule | Office | 2021 | 15 | 27 | $4,374 | $1,034 | 23.6% |
About Dr. Robert Watson, MD
Dr. Robert Watson, MD is a Family Medicine healthcare provider based in El Dorado, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417060286.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Watson, MD has received a total of $4,443 in payments from pharmaceutical and medical device companies, with $607.41 received in 2024. These payments were reported across 322 transactions from 42 companies. The most common payment nature is "Food and Beverage" ($4,353).
As a Medicare-enrolled provider, Watson has provided services to 2,624 Medicare beneficiaries, totaling 5,474 services with total Medicare billing of $318,410. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location El Dorado, AR
- Active Since 08/16/2006
- Last Updated 07/08/2007
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1417060286
Products in Payments
- VRAYLAR (Drug) $693.29
- Ozempic (Drug) $271.00
- LINZESS (Drug) $165.43
- XIFAXAN (Drug) $142.38
- TRELEGY ELLIPTA (Drug) $132.42
- MOUNJARO (Drug) $130.84
- QUDEXY XR Topiramate Extended Release Capsules (Drug) $126.07
- UBRELVY (Drug) $124.72
- RYBELSUS (Drug) $124.03
- FARXIGA (Drug) $113.72
- EMGALITY (Drug) $109.37
- QULIPTA (Drug) $107.48
- TRULICITY (Drug) $104.34
- Victoza (Drug) $98.74
- EUCRISA (Drug) $97.22
- JARDIANCE (Drug) $82.39
- JANUVIA (Drug) $79.54
- CHANTIX (Drug) $76.46
- SUTAB (Drug) $73.31
- Synthroid (Drug) $68.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in El Dorado
Crystal Faudere, D.o, D.O
Family Medicine — Payments: $15,929
Family Medicine $15,929
Diane Nightengale, M.d, M.D
Family Medicine — Payments: $13,382
Family Medicine $13,382
Dr. Matthew Callaway, Md, MD
Family Medicine — Payments: $4,432
Family Medicine $4,432
Dr. Deanna Hopson, M.d, M.D
Family Medicine — Payments: $3,382
Family Medicine $3,382
Dr. Christina Cooper, M.d, M.D
Family Medicine — Payments: $3,378
Family Medicine $3,378
Dr. Gary Bevill, Md, MD
Family Medicine — Payments: $3,122
Family Medicine $3,122